Poolbeg Pharma's Oral POLB 001 for Cancer Immunotherapy CRS Prevention Could Tap $10B Market

Name: Poolbeg Pharma's Oral POLB 001 for Cancer Immunotherapy CRS Prevention Could Tap $10B Market
Uploaded: 2024-02-12T15:32:52.253700+00:00
Duration: 111 s
Channel: Vox Markets
Description: Poolbeg Pharma's Oral POLB 001 for Cancer Immunotherapy CRS Prevention Could Tap $10B Market

2 views

2 years ago